160388-54-5

Usage

Uses

Used in Pharmaceutical Industry:
4-(1H-1,2,4-TRIAZOL-1-YLMETHYL)BENZOIC ACID is used as a building block for the synthesis of biologically active compounds due to its unique 1,2,4-triazole ring, which can be incorporated into various drug molecules to enhance their pharmacological properties.
Used in Coordination Chemistry:
4-(1H-1,2,4-TRIAZOL-1-YLMETHYL)BENZOIC ACID is used as a ligand for coordinating metal ions, leveraging its triazole ring to form stable complexes that can be applied in various chemical and catalytic processes.
Used in Drug Design:
4-(1H-1,2,4-TRIAZOL-1-YLMETHYL)BENZOIC ACID is used as a pharmacophore in drug design, where its structural features can be exploited to create new drugs with improved efficacy and selectivity.
Used in Drug Delivery Systems:
4-(1H-1,2,4-TRIAZOL-1-YLMETHYL)BENZOIC ACID is used as a component in the development of novel drug delivery systems, taking advantage of its carboxylic acid group to facilitate targeted and controlled release of therapeutic agents.
Used in Materials Science:
4-(1H-1,2,4-TRIAZOL-1-YLMETHYL)BENZOIC ACID is used in the creation of new materials with specific properties, such as those with enhanced stability or reactivity, by incorporating its unique molecular structure into the material's composition.

InChI:InChI=1/C10H9N3O2/c14-10(15)9-3-1-8(2-4-9)5-13-7-11-6-12-13/h1-4,6-7H,5H2,(H,14,15)

Upstream product

• 288-88-0 1,2,4-Triazole 
• 6232-88-8 4-bromomethylbenzoic Acid 
• 26496-94-6 Ethyl 4-(bromomethyl)benzoate 
• 160388-64-7 ethyl 4-(1H-1,2,4-triazol-1-ylmethyl)benzoate 

Downstream Products

• 1612868-48-0 [copper(II)(4-(1H-1,2,4-trizol-1-ylmethyl)benzoate)(1,10-phenanthroline)(HCO₂)]_n 
• 1612868-46-8 copper(II) (4-(1H-1,2,4-trizol-1-ylmethyl)benzoicacid)₂Cl₂(H₂O) 
• 1447961-06-9 (3-(4-((1H-1,2,4-triazol-1-yl)methyl)-N-hydroxybenzamido)-1-(3,4-dichlorophenyl)propyl)phosphonic acid 
• 870766-45-3 methyl 4-(1H-1,2,4-triazol-1-ylmethyl)benzoate 

Relevant academic research and scientific papers

Copper(II) complexes with 4-(1H-1, 2, 4-trizol-1-ylmethyl) benzoic acid: Syntheses, crystal structures and antifungal activities

Reaction of Cu(II) with an asymmetric semi-rigid organic ligand 4-(1H-1, 2, 4-trizol-1-ylmethyl) benzoic acid (HL), yielded five compounds, [Cu 0.5L]n (1), [Cu(HL)2Cl2]n (2), [Cu(HL)2Cl2(H2O)] (3), [Cu(L) 2(H2O)]n (4) and [Cu(L)(phen)(HCO 2)]n (5), which have been fully characterized by infrared spectroscopy, elemental analysis, and single-crystal X-ray diffraction. As for compounds 1, 2 and 5, Cu(II) is bridged through HL, Cl-, and formic acid, respectively, featuring 1D chain-structure. In compound 3, Cu(II) with hexahedral coordination sphere is assembled through hydrogen-bonding into 3D supramolecular framework. In compound 4, 1D chain units -Cu-O-Cu-O- are ligand-bridged into a 3D network. All compounds were tested on fungi (Fusarium graminearum, Altemaria solani, Macrophoma kawatsukai, Alternaria alternata and Colletotrichum gloeosporioides). Compound 1 exhibits a better antifungal effect compared to other compounds. An effect of structure on the antifungal activity has also been correlated.

FIBROSIS INHIBITOR

Medicament being useful as a fibrosis inhibitor for organs or tissues, which comprises a compound of the formula (I): wherein Ring Z is optionally substituted pyrrole ring, etc.; W2 is -CO-, -SO2-, optionally substituted C1-C4 alkylene, etc.; Ar2 is optionally substituted aryl, etc.; W1 and Ar1 mean the following (1) and (2):(1) W1 is optionally substituted C1-C4 alkylene, etc.; Ar1 is optionally substituted bicyclic heteroaryl having 1 to 4 nitrogen atoms as ring-forming atoms:(2) W1 is optionally substituted C2-C5 alkylene, optionally substituted C2-C5 alkenylene, etc.; and Ar1 is aryl or monocyclic heteroaryl, which is substituted by carboxyl, alkoxycarbonyl, etc. at the ortho- or meta-position thereof with respect to the binding position of W1, or a pharmaceutically acceptable salt thereof.

Pyrrole derivatives

Pyrrole derivatives represented by the following formula: wherein Ring Z is an optionally substituted pyrrole ring, etc.; W2 is —CO—, —SO2—, an optionally substituted C1-C4 alkylene, etc.; Ar2 is an optionally substituted aryl, etc.; W2 and Ar1 mean the following (1) and (2): (1) W1 is an optionally substituted C1-C4 alkylene, etc.; Ar1 is an optionally substituted bicyclic heteroaryl having 1 to 4 nitrogen atoms as ring-forming atoms: (2) W1 is an optionally substituted C2-C5 alkylene, an optionally substituted C2-C5 alkenylene, etc.; and Ar1 is an aryl or monocyclic heteroaryl, which are substituted by carboxyl, an alkoxycarbonyl, etc. at the ortho- or meta-position thereof with respect to the binding position of W1, or a pharmaceutically acceptable salt thereof These compounds are useful as medicaments such as a fibrosis inhibitor for organs or tissues.

Non-steroidal antiinflammatory agents. Synthesis and enzyme inhibition of 2-[4-(heteroarylmethyl)phenyl]propanoic acids and analogues

Some 2-[4-(heteroarylmethyl)phenyl]propanoic acids and phenylacetic and benzoic analogues have been synthesized. All above acids were tested for their inhibitory activity on lipoxygenase and cyclooxygenase, in comparison with NDGA and tolmetin. 2-[4-(Thie